Invivyd to Host Conference Call to Announce Results from Interim Analysis of Phase 3 DECLARATION Clinical Trial on November 23, 2026
Key Highlights
- ➤Invivyd (IVVD) will announce interim Phase 3 DECLARATION results November 23
- ➤Investor call scheduled for 8:30 a.m. ET following a 7:00 a.m. release
- ➤VYD2311 is being developed as a COVID-19 prophylactic and therapeutic monoclonal antibody
- ➤VYD2311 may enable intramuscular administration through its pharmacokinetic profile and antiviral potency
NEW HAVEN, Conn., Nov. 22, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will host an investor call to announce results from an interim analysis of the ongoing Phase 3 DECLARATION clinical trial on Monday, November 23, 2026 at 8:30 a.m. ET. Invivyd will issue a press release regarding the results at approximately 7:00 a.m. ET that morning.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
Get started
Create a free account to read the full story.
